SIGMAR1: IHC Expression in Cancer and Radioligand Target Profile
SIGMAR1, sigma non-opioid intracellular receptor 1, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, SIGMAR1 staining is highest in thyroid cancer (100% of samples positive), colorectal cancer (100% of samples positive) and liver cancer (91% of samples positive). Evidence on whether SIGMAR1 internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is SIGMAR1 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze SIGMAR1 freeIs SIGMAR1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in thyroid cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
SIGMAR1 IHC staining by cancer type
Protein expression of SIGMAR1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Thyroid Cancer | 1.00 | High | 100% |
| Colorectal Cancer | 0.75 | High | 100% |
| Liver Cancer | 0.73 | High | 91% |
| Cervical Cancer | 0.64 | High | 100% |
| Ovarian Cancer | 0.61 | High | 100% |
| Bladder Cancer | 0.55 | High | 82% |
| Breast Cancer | 0.50 | Medium | 100% |
| Endometrial Cancer | 0.50 | Medium | 83% |
| Melanoma | 0.44 | Medium | 83% |
| Skin Cancer | 0.42 | Medium | 91% |
| Pancreatic Cancer | 0.42 | Medium | 92% |
| Head and Neck Cancer | 0.42 | Medium | 75% |
| Neuroendocrine Tumors | 0.42 | Medium | 75% |
| Lung Cancer | 0.42 | Medium | 75% |
| Gastric Cancer | 0.37 | Medium | 70% |
| Glioma | 0.33 | Medium | 75% |
| Prostate Cancer | 0.31 | Medium | 58% |
| Lymphoma | 0.25 | Medium | 58% |
| Kidney Cancer | 0.19 | Low | 50% |
| Testicular Cancer | 0.04 | Low | 11% |
Is SIGMAR1 internalized?
Uncertain. Insufficient literature found.
SIGMAR1 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for SIGMAR1 yet. Search ClinicalTrials.gov for SIGMAR1 trials.
SIGMAR1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SIGMAR1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
SIGMAR1 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.21 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related thyroid cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · SSTR2 · EPCAM · EGFR · ITGAV · STEAP2 · Nectin-4 (NECTIN4)
See all radioligand therapy targets in thyroid cancer.
See how SIGMAR1 ranks against 15,000 targets for your indication.
Analyze SIGMAR1 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.